Psoriatic arthritis (PsA), often accompanied by nail psoriasis, spine, enthesitis and iritis, is a typical complication of psoriasis. PsA leads to the destruction and/or ankylosis of the peripheral joints or spine, resulting in poor quality of life. Interleukin (IL)-23, IL-17 and tumour necrosis factor play pivotal roles in the pathogenesis of PsA and are targets for its treatment. Biological disease-modifying antirheumatic drugs targeting these cytokines and targeted synthetic disease-modifying antirheumatic drugs targeting Janus kinases are available and widely used in clinical practice. Despite the availability of these drugs, there are still unmet needs; for example, patients often resist treatment and relapse or develop intolerance. Bimekizumab is a humanized monoclonal IgG1 antibody that selectively and directly inhibits IL-17A and IL-17F expression. Recently, the efficacy and tolerability of bimekizumab have been reported in several large clinical trials, including two phase III studies. Bimekizumab brings rapid symptom relief and is effective in patients who are biologic-naïve and those who have inadequate responses or become intolerable to tumour necrosis factor inhibitors and require discontinuation; therefore, it is expected to be a novel blockbuster to overcome the unmet needs of PsA.